Akari Hopes Tick-Based Drug Will Be Safer, Cheaper Than Alexion's Soliris

Akari Therapeutics is looking to ticks to provide a new therapy that it hopes will offer a safer and cheaper alternative to Alexion Pharmaceuticals' Soliris for some rare orphan diseases.

Tick

NASDAQ-listed Akari Therapeutics PLC –which has a pipeline of tick-derived molecules selected to suppress mediators of chronic inflammation in wide range of orphan disorders – expects a Phase II topline data readout soon for its lead candidate that it hopes will open the way for Phase III trialing later this year in the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH).

Akari’s lead molecule is Coversin, a recombinant small protein (16,740 Da) derived from a native protein discovered in the saliva...

More from Clinical Trials

More from R&D